ClinicalTrials.gg
CompletedNCT04459598Updated Jun 28, 2022Results posted

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

A Phase 1 interventional study of Efavirenz and Quizartinib in Healthy Subjects, Drug-drug Interaction and Pharmacokinetics, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Daiichi Sankyo Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.

Read the detailed description

In vitro, quizartinib is metabolized primarily by CYP3A. Therefore, co-administration of quizartinib with CYP3A inducers may decrease quizartinib exposure. This study will assess the effect of a moderate CYP3A inducer efavirenz on the single dose (60 mg) quizartinib pharmacokinetics in healthy participants.

02

Conditions studied

  • Healthy Subjects
  • Drug-drug Interaction
  • Pharmacokinetics
  • Quizartinib

Keywords

  • Healthy Subjects
  • Drug-drug Interaction
  • Pharmacokinetics
  • Quizartinib
  • CYP3A Inducer
03

In context

Lead sponsor

Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants 18 to 55 years of age (inclusive), with a (BMI) of 18 kg/m\^2 to 32 kg/m\^2 (inclusive) and with a minimum body weight of 45 kg at Screening.
  • In females, documented surgical sterilization, status for at least 1 year (follicle stimulating hormone [FSH] > 40 mIU/mL serum at Screening), or agreement to use an approved form of
  • In males, agreement to avoid sperm donation for 6 months days after the dose of quizartinib
  • Participants must agree to refrain from donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to Screening, and from 6 weeks prior to Screening.
  • Liver function test results must be below the . levels must be ≥ 11.5 g/dL for female participants and ≥ 12.5 g/dL for male participants.
  • All participants must be willing to refrain from consuming grapefruit/ grapefruit juice, Seville oranges, and pomegranates/pomegranate juice 10 days before the dose of the study drug is given on Day 1 until end-of-study.

Exclusion criteria

Exclusion Criteria:

  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormality) that could interfere with participant's safety, obtaining or compliance to the study procedures.
  • Laboratory results (serum chemistry, hematology, and urinalysis) outside the normal range, if considered by the investigator. Estimated (eGFR) \< 90 mL/min at screening.
  • Women who are pregnant or breastfeeding
  • Use of any drugs or substances known to be inhibitors or inducers of /5 within 28 days from the first dose or 5 half-lives, if known, of the drugs or substances, whichever is greater, prior to quizartinib administration and during the study.
  • Receipt of any prescribed or over-the-counter (OTC) systemic, herbal (including St John's wort), or topical medication within 14 days of quizartinib administration, or any expectation of requiring use of such medication while participating in the study is prohibited.
  • Presence or history of clinically severe adverse reaction to any drug
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (with the exception of appendectomy, hernia repair, and/or cholecystectomy)
  • History of any cancer, except non-melanoma skin cancer, or resected nonmetastatic cancer with no evidence of disease accepted by the Investigator and Sponsor medical monitor
  • A positive drugs of abuse screen from a urine ethanol test (unless the drug is medically prescribed by a licensed health care provider) or alcohol breath test at Screening or at Check-in on Day -1 or a participant who will not agree to smoke ≤10 cigarettes or equivalent per day from Screening up to Enrollment, and is unable to be restricted to ≤5 cigarettes per day and for 6 hours post dose during their period of residence in the clinical unit
  • Concomitant use of medications known to affect the elimination of serum creatinine (e.g., trimethoprim or cimetidine) and inhibitors of renal tubular secretion (eg, probenecid) within 14 days or 5 half-lives, if known, of the drugs, whichever is greater, prior to quizartinib administration
  • History or presence of an abnormal (ECG), which, in the investigator's opinion, is clinically significant and/or a corrected for heart rate using Fridericia's formula >450 milliseconds (ms) at Screening.
  • Use of drugs with a risk of QT interval prolongation or torsade de pointes within 14 days of Day -1 (or 5 drug half-lives, if 5 drug half-lives are expected to exceed 14 days)
  • Consumption of alcohol- and caffeine-containing beverages within 72 h prior to check-in and during confinement
  • Positive serology for surface antigen (HBsAg) and (healthy participants), hepatitis A virus (HAV) immunoglobulin M, or antihuman immunodeficiency virus () Type 1 and Type 2 (all subjects)
  • Loss of more than 450 mL blood during the 3 months before the trial (eg, as a blood donor)
  • Current enrollment in or have not yet completed at least 30 days or 5 elimination half-lives, whichever is longer, since receiving an device or product, or receipt of other investigational agents within 30 days of quizartinib
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Efavirenz 600 mg + Quizartinib 60 mg

    Participants who received efavirenz 600 mg once daily (QD) for 34 days and a single, oral dose of quizartinib 60 mg on Day 15 concurrently with efavirenz.

    Drug: Efavirenz · Drug: Quizartinib

  • Active comparator
    Quizartinib 60 mg

    Participants who received a single, oral dose of quizartinib 60 mg on Day 1.

    Drug: Quizartinib

Interventions

  • Single oral dose, 600-mg tablet

  • Single oral dose, 60 mg (2 x 30 mg) tablets

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) Following Single Dose of Quizartinib With or Without Efavirenz

    Maximum Plasma Concentration (Cmax) is defined as the maximum observed plasma concentration and was an observed value for the study. Cmax was assessed for Quizartinib and active metabolite AC886.

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose

  2. Time to Maximum Plasma Concentration (Tmax) Following Single Dose of Quizartinib With or Without Efavirenz

    Time of Maximum Plasma Concentration (Tmax) is defined as time of maximum observed plasma concentration and was an observed value from the study. Tmax was assessed for Quizartinib and active metabolite AC886.

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose

  3. Area Under the Plasma Concentration-Time Curve up to the Last Quantifiable Concentration Post-Dose (AUClast) Following Single Dose of Quizartinib With or Without Efavirenz

    Area Under the Plasma Concentration-Time Curve up to the Last Quantifiable Concentration Post-Dose (AUClast) is defined as AUC from time 0 to the last measurable concentration, as calculated by the linear up-log down trapezoidal method and was calculated using non-compartmental analysis. AUClast was assessed for Quizartinib and active metabolite AC886.

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose

  4. Area Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) Following Single Dose of Quizartinib With or Without Efavirenz

    Area Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) is defined as area under the plasma concentration-time curve from the time of dosing extrapolated to infinity and was calculated using non-compartmental analysis. AUCinf was assessed for Quizartinib and active metabolite AC886.

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose

  5. Terminal Half-Life (t1/2) Following Single Dose of Quizartinib With or Without Efavirenz

    Terminal Elimination Half-Life (t1/2) is defined as terminal elimination half-life and was calculated using non-compartmental analysis. AUClast was assessed for Quizartinib and active metabolite AC886. Half-life (t1/2) was assessed for Quizartinib and active metabolite AC886.

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose

  6. Metabolite to Parent Ratio (MPR) Based on Area Under the Curve for Active Metabolite AC886 Following Single Dose of Quizartinib With or Without Efavirenz

    AUCinf is defined as area under the plasma concentration-time curve from the time of dosing extrapolated to infinity and AUClast is defined as AUC from time 0 to the last measurable concentration, as calculated by the linear up-log down trapezoidal method. MPR is defined as a metabolite to parent ratio with metabolite as the numerator and the parent as the denominator. MPR corrected for molecular weight of AC886 of AUCinf and AUClast are reported and were calculated using non-compartmental analysis.

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose

  7. Total Apparent Clearance (CL/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz

    Total Apparent Clearance (CL/F) is defined as total apparent clearance and was calculated using non-compartmental analysis.

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose

  8. Volume of Distribution in the Terminal Phase (Vz/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz

    Volume of Distribution in the Terminal Phase (Vz/F) is defined as volume of distribution in the terminal phase and was calculated using non-compartmental analysis.

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events Following Single Dose of Quizartinib With or Without Efavirenz

    A Treatment-Emergent Adverse Events (TEAE) is defined as any event not present prior to the initiation of the drug treatment of the drug treatment or any event already present that worsens in either intensity or frequency following exposure to the drug treatment. Number of any TEAE that is related and unrelated to study medication is presented.

    Time frame: Baseline up to 30 days post last dose, up to approximately 2 months

07

Results

Posted Jun 6, 2022

Participant flow

A total of 32 participants who met all inclusion criteria and no exclusion criteria were enrolled from 19 Aug 2020 to 14 Oct 2020 at 1 clinic in the United States.

Participant flow — Overall Study
MilestoneEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Started1616
Completed1515
Not completed11
Withdrew: Adverse event11

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) Following Single Dose of Quizartinib With or Without Efavirenz

Maximum Plasma Concentration (Cmax) is defined as the maximum observed plasma concentration and was an observed value for the study. Cmax was assessed for Quizartinib and active metabolite AC886.

Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) Following Single Dose of Quizartinib With or Without Efavirenz
ng/mLEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Quizartinib130.0 ± 36.1238.0 ± 76.9
AC88611.0 ± 5.3534.4 ± 18.2
Statistical analysis
  • Efavirenz 600 mg + Quizartinib 60 mg vs Quizartinib 60 mg · Ratio (%) of geometric ls mean: 55.24 · 90% CI 45.24 to 67.46For the comparison, the Efavirenz + Quizartinib treatment group represents the numerator and Quizartinib only treatment group represents the denominator.
  • Efavirenz 600 mg + Quizartinib 60 mg vs Quizartinib 60 mg · Ratio (%) of geometric ls mean: 32.37 · 90% CI 23.79 to 44.05For the comparison, the Efavirenz + Quizartinib treatment group represents the numerator and Quizartinib only treatment group represents the denominator.
PrimaryTime to Maximum Plasma Concentration (Tmax) Following Single Dose of Quizartinib With or Without Efavirenz

Time of Maximum Plasma Concentration (Tmax) is defined as time of maximum observed plasma concentration and was an observed value from the study. Tmax was assessed for Quizartinib and active metabolite AC886.

Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) Following Single Dose of Quizartinib With or Without Efavirenz
hoursEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Quizartinib2.0 (2.0 to 4.0)4.0 (2.0 to 4.2)
AC8864.0 (2.0 to 4.0)4.0 (4.0 to 24.0)
PrimaryArea Under the Plasma Concentration-Time Curve up to the Last Quantifiable Concentration Post-Dose (AUClast) Following Single Dose of Quizartinib With or Without Efavirenz

Area Under the Plasma Concentration-Time Curve up to the Last Quantifiable Concentration Post-Dose (AUClast) is defined as AUC from time 0 to the last measurable concentration, as calculated by the linear up-log down trapezoidal method and was calculated using non-compartmental analysis. AUClast was assessed for Quizartinib and active metabolite AC886.

Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose
Reported as:
Mean · ng*h/mL
Area Under the Plasma Concentration-Time Curve up to the Last Quantifiable Concentration Post-Dose (AUClast) Following Single Dose of Quizartinib With or Without Efavirenz
ng*h/mLEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Quizartinib2730 ± 116023600 ± 8420
AC886185 ± 1774110 ± 1320
Statistical analysis
  • Efavirenz 600 mg + Quizartinib 60 mg vs Quizartinib 60 mg · Ratio (%) of geometric ls mean: 11.11 · 90% CI 8.47 to 14.56For the comparison, the Efavirenz + Quizartinib treatment group represents the numerator and Quizartinib only treatment group represents the denominator.
  • Efavirenz 600 mg + Quizartinib 60 mg vs Quizartinib 60 mg · Ratio (%) of geometric ls mean: 3.67 · 90% CI 2.47 to 5.45For the comparison, the Efavirenz + Quizartinib treatment group represents the numerator and Quizartinib only treatment group represents the denominator.
PrimaryArea Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) Following Single Dose of Quizartinib With or Without Efavirenz

Area Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) is defined as area under the plasma concentration-time curve from the time of dosing extrapolated to infinity and was calculated using non-compartmental analysis. AUCinf was assessed for Quizartinib and active metabolite AC886.

Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose
Reported as:
Mean · ng*h/mL
Area Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) Following Single Dose of Quizartinib With or Without Efavirenz
ng*h/mLEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Quizartinib2760 ± 117026000 ± 9880
AC886208 ± 1834540 ± 1410
Statistical analysis
  • Efavirenz 600 mg + Quizartinib 60 mg vs Quizartinib 60 mg · Ratio (%) of geometric ls mean: 10.29 · 90% CI 7.73 to 13.70For the comparison, the Efavirenz + Quizartinib treatment group represents the numerator and Quizartinib only treatment group represents the denominator.
  • Efavirenz 600 mg + Quizartinib 60 mg vs Quizartinib 60 mg · Ratio (%) of geometric ls mean: 3.88 · 90% CI 2.62 to 5.76For the comparison, the Efavirenz + Quizartinib treatment group represents the numerator and Quizartinib only treatment group represents the denominator.
PrimaryTerminal Half-Life (t1/2) Following Single Dose of Quizartinib With or Without Efavirenz

Terminal Elimination Half-Life (t1/2) is defined as terminal elimination half-life and was calculated using non-compartmental analysis. AUClast was assessed for Quizartinib and active metabolite AC886. Half-life (t1/2) was assessed for Quizartinib and active metabolite AC886.

Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose
Reported as:
Mean · hours
Terminal Half-Life (t1/2) Following Single Dose of Quizartinib With or Without Efavirenz
hoursEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Quizartinib23.8 ± 7.4136 ± 40.1
AC88611.9 ± 5.5135 ± 33.5
PrimaryMetabolite to Parent Ratio (MPR) Based on Area Under the Curve for Active Metabolite AC886 Following Single Dose of Quizartinib With or Without Efavirenz

AUCinf is defined as area under the plasma concentration-time curve from the time of dosing extrapolated to infinity and AUClast is defined as AUC from time 0 to the last measurable concentration, as calculated by the linear up-log down trapezoidal method. MPR is defined as a metabolite to parent ratio with metabolite as the numerator and the parent as the denominator. MPR corrected for molecular weight of AC886 of AUCinf and AUClast are reported and were calculated using non-compartmental analysis.

Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose
Reported as:
Mean · ratio
Metabolite to Parent Ratio (MPR) Based on Area Under the Curve for Active Metabolite AC886 Following Single Dose of Quizartinib With or Without Efavirenz
ratioEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
MPR AUClast0.0675 ± 0.04030.186 ± 0.0753
MPR AUCinf0.0762 ± 0.03950.1880 ± 0.0777
PrimaryTotal Apparent Clearance (CL/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz

Total Apparent Clearance (CL/F) is defined as total apparent clearance and was calculated using non-compartmental analysis.

Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose
Reported as:
Mean · L/h
Total Apparent Clearance (CL/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz
L/hEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Total Apparent Clearance (CL/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz12.210 ± 7.69371.1849 ± 0.51388
PrimaryVolume of Distribution in the Terminal Phase (Vz/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz

Volume of Distribution in the Terminal Phase (Vz/F) is defined as volume of distribution in the terminal phase and was calculated using non-compartmental analysis.

Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 288, 360, 432, and 504 hours post-quizartinib dose
Reported as:
Mean · L
Volume of Distribution in the Terminal Phase (Vz/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz
LEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Volume of Distribution in the Terminal Phase (Vz/F) for Quizartinib Following Single Dose of Quizartinib With or Without Efavirenz359.9 ± 102.23214.9 ± 59.82
SecondaryNumber of Participants With Treatment-emergent Adverse Events Following Single Dose of Quizartinib With or Without Efavirenz

A Treatment-Emergent Adverse Events (TEAE) is defined as any event not present prior to the initiation of the drug treatment of the drug treatment or any event already present that worsens in either intensity or frequency following exposure to the drug treatment. Number of any TEAE that is related and unrelated to study medication is presented.

Time frame:
Baseline up to 30 days post last dose, up to approximately 2 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events Following Single Dose of Quizartinib With or Without Efavirenz
ParticipantsEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
Number of Participants With Treatment-emergent Adverse Events Following Single Dose of Quizartinib With or Without Efavirenz135

Adverse events

Collected over Adverse events were collected from the date of signing the informed consent form up to 30 days after last dose, up to 2 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efavirenz 600 mg + Quizartinib 60 mg0/16 (0%)0/16 (0%)13/16 (81.3%)
Quizartinib 60 mg0/16 (0%)0/16 (0%)5/16 (31.3%)
Most frequent other events
Showing 10 of 33
Most frequent other events
EventEfavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mg
HeadacheNervous system disorders6/162/16
DizzinessNervous system disorders5/160/16
NauseaGastrointestinal disorders3/161/16
FlatulenceGastrointestinal disorders3/160/16
Abnormal dreamsPsychiatric disorders2/160/16
Arthropod biteInjury, poisoning and procedural complications2/160/16
ParaesthesiaNervous system disorders1/161/16
Disturbance in attentionNervous system disorders1/160/16
Dizziness posturalNervous system disorders1/160/16
ConstipationGastrointestinal disorders0/161/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Efavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mgTotal
<=18 years000
Between 18 and 65 years161632
>=65 years000
Age, Continuous
Age, Continuous(years)Efavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mgTotal
Mean40 ± 10.0538.7 ± 10.2239.6 ± 10.01
Sex: Female, Male
Sex: Female, Male(Participants)Efavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mgTotal
Female156
Male151126
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Efavirenz 600 mg + Quizartinib 60 mgQuizartinib 60 mgTotal
American Indian or Alaska Native202
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American9918
White5712
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Oct 2020, 1 month.

Results were first posted in Jun 2022, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2020
First posted
Jul 7, 2020
StartActual
Aug 19, 2020
Primary completionActual
Oct 14, 2020
CompletionActual
Oct 14, 2020
Results first posted
Jun 6, 2022
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04459598
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Aug 19, 2020
Primary completion
Oct 14, 2020
Completion
Oct 14, 2020
Results posted
Jun 6, 2022
Last update
Jun 28, 2022

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efavirenz · Quizartinib

Start the discussion